3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Ovarian Neoplasms
3
Breast Neoplasms
3
Neoplasms
2
Uterine Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoadjuvant Therapy
1
Lung Neoplasms
1
Kenny-Caffey syndrome, Type 1
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
Gemcitabine
9
Carboplatin
8
Paclitaxel
7
Capecitabine
7
Irinotecan
6
pembrolizumab
3
Radiotherapy
3
Oxaliplatin
3
Fluorouracil
3
Filgrastim
3
Cisplatin
3
Bevacizumab
3
etoposide phosphate
2
Surveys and Questionnaires
2
Peripheral Blood Stem Cell Transplantation
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Genetic Testing
2
FAPI-46
2
Etoposide
2
Erlotinib Hydrochloride
2
Docetaxel
2
Cyclophosphamide
2
Amifostine
2
Albumin-Bound Paclitaxel
2
tislelizumab
1
tegafur-gimeracil-oteracil
1
spartalizumab
1
sintilimab
1
erythromycin propionate-N-acetylcysteinate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms, Unknown Primary
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled